These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11522118)

  • 1. Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?
    Kraft WK; Waldman SA
    Drug Saf; 2001; 24(9):637-43. PubMed ID: 11522118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ethics of postmarketing observational studies of drug safety under section 505(o)(3) of the Food, Drug, and Cosmetic Act.
    Evans BJ
    Am J Law Med; 2012; 38(4):577-606. PubMed ID: 23356097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.
    Allan MC
    J Pharm Technol; 1992; 8(4):162-7. PubMed ID: 10121011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A primer of drug safety surveillance: an industry perspective. Part II: Product labeling and product knowledge.
    Allan MC
    J Pharm Technol; 1992; 8(5):198-202. PubMed ID: 10171208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.
    Stang PE; Ryan PB; Racoosin JA; Overhage JM; Hartzema AG; Reich C; Welebob E; Scarnecchia T; Woodcock J
    Ann Intern Med; 2010 Nov; 153(9):600-6. PubMed ID: 21041580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
    Kesselheim AS; Mello MM
    Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory innovation in postmarketing risk assessment and management.
    Staffa JA; Dal Pan GJ
    Clin Pharmacol Ther; 2012 Mar; 91(3):555-7. PubMed ID: 22297386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A primer of drug safety surveillance: an industry perspective. Part III: Managing adverse-event data.
    Allan MC
    J Pharm Technol; 1992; 8(6):259-73. PubMed ID: 10122649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.
    Cope JU; Rosenthal GL; Weinel P; Odegaard A; Murphy DM
    Pediatrics; 2015 Dec; 136(6):1125-31. PubMed ID: 26598453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug events: identification and attribution.
    Rogers AS
    Drug Intell Clin Pharm; 1987 Nov; 21(11):915-20. PubMed ID: 3678067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies.
    Fan Y; Sun B; Agarwal S; Zhang L
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S193-204. PubMed ID: 27385175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.